Perspective Therapeutics (CATX) Projected to Post Earnings on Wednesday

Perspective Therapeutics (NYSE:CATX) will likely be issuing its quarterly earnings data after the market closes on Wednesday, March 26th. Analysts expect Perspective Therapeutics to post earnings of ($0.26) per share for the quarter.

Perspective Therapeutics Price Performance

CATX opened at $2.52 on Tuesday. The firm’s 50-day simple moving average is $3.01 and its 200-day simple moving average is $6.66. Perspective Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.05.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CATX shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday, March 19th. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Monday, March 17th. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Perspective Therapeutics currently has an average rating of “Buy” and a consensus target price of $14.56.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.